Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma

Palmieri, Vincenzo O.; Grattagliano, Ignazio; Minerva, Francesco; Pollice, Silvana; Palasciano, Giuseppe; Portincasa, Piero

doi:10.1016/j.jss.2008.09.029

Cited by 24 publications

(27 citation statements)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the aminopyrine breath test is a well established dynamic test of mitochondrial liver function, correlating with outcome in patients with chronic liver disease [8] and frequently used to estimate functional hepatic reserve in patients undergoing liver resection with high accuracy [9, 18 -20], we assume a stable hepatic function in our patients following mainly superselective locoregional therapy of HCC which results in a diligent embolization of hepatic tumor without affecting surrounding liver tissue significantly. In concordance with earlier studies we have demonstrated an impaired aminopyrine metabolism in patients with HCC already at baseline [17,21]. A higher score in the Child-Pugh classification in the individual patient on the other hand can be solely the result of poor clinical performance of the patient (ascites, hepatic encephalopathy) while the metabolic liver function might still be preserved.…”

Section: Discussionsupporting

confidence: 92%

“…An acute and transient decrease in intrinsic hepatic clearance of indocyanine green without significant changes in short-term galactose elimination capacity and the aminopyrine breath test has been published from a cohort of 15 patients with HCC undergoing TACE. In a cohort of 14 patients with HCC a decrease in 13 C- methacetin breath test results was documented following TACE reflecting an impairment of mitochondrial function [17]. The quantitative assessment of liver function by a 13 C-aminopyrine breath test in the presented study did not show significant changes following TACE.…”

Section: Discussionmentioning

confidence: 47%

See 1 more Smart Citation

Assessment and monitoring of liver function by 13C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

Liver function assessment with (13)C-aminopyrine breath test and Child-Pugh-classification following TACE was discordant in a large proportion of patients. Whether a quantification of mitochondrial liver function in patients planned to undergo locoregional treatment of HCC in liver cirrhosis is helpful in the prediction of postprocedural liver decompensation needs to be addressed in larger prospective clinical trials.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 47%

Assessment and monitoring of liver function by 13C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[119][120][121][122][123][124][125][126] Methacetin is rapidly metabolized primarily by CYP1A2 in the liver and in small doses lacks toxicity making it an ideal substrate for evaluating cytochrome P450 enzyme activity.…”

Section: Breath Tests For Cyp450 Enzymesmentioning

confidence: 99%

An Update on 13C-Breath Tests: The Transition to Acceptability into Clinical Practice

Modak

2013

Volatile Biomarkers

View full text Add to dashboard Cite

“…This breath test has also been seen to discriminate the hepatic function capacity in patients with chronic liver disease 8, 9. Metabolism of 13 C‐methacetin decreases following transcatheter arterial chemoembolization but not after radiofrequency ablation in treating patients with cirrhosis who had hepatocellular carcinoma 10. The 13 C‐methacetin breath test was shown to provide a rapid assessment of liver function in patients with acute liver failure 11.…”

Section: Commentsmentioning

confidence: 99%

Reversibility of posttransplantation diabetes mellitus following liver transplantation

Perkins¹

2009

Liver Transpl

View full text Add to dashboard Cite

Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation. Ahn HY, Cho YM, Yi NJ, Suh KS, Lee KU, Park KS, et al. J Korean Med Sci 2009;24:567-570. AbstractPost-transplantation diabetes mellitus (PTDM) is reversible in a considerable number of patients. We examined the prevalence and predictive factors of transient PTDM following liver transplantation. Forty-two of 74 PTDM patients showed the clinical features of transient PTDM. Compared with the persistent PTDM patients, they were characterized by younger age at the time of transplantation (49 Ϯ 7 vs. 53 Ϯ 8 yr, P Ͻ 0.05), longer time before the development of PTDM (44 Ϯ 59 vs. 13 Ϯ 20 days, P Ͻ 0.05), lower rate of hepatitis c virus seropositivity (0.0 vs. 9.4%, P Ͻ 0.05), and use of mycophenolate mofetil (59.5 vs. 28.1%, P Ͻ 0.05). Among these risk factors, age at the time of transplantation is the single independent predictive factor associated with the reversibility of PTDM. COMMENTSNew-onset diabetes mellitus (NODM) develops in approximately 15%-30% of patients following liver transplantation.1-4 The incidence of NODM has been reported as high as 42% in patients infected with hepatitis C virus.5 Does NODM cause increased morbidity or mortality following liver transplantation, and what factors indicate a possibility that it can resolve? Marchetti 1 suggested that NODM is associated with increased mortality rates and higher risk of infection. Navasa et al. 6 reported that patients with posttransplantation diabetes mellitus (not all had NODM; some patients had preexisting diabetes mellitus) experienced a higher number of rejection episodes during the first posttransplant year than did patients without diabetes mellitus. The mortality rate of patients with diabetes mellitus was significantly higher in the second posttransplant year than that of patients without diabetes mellitus. Baid et al. 7 found that posttransplant diabetes mellitus was associated with a significantly increased mortality rate. Steinmuller et al. 8 reported that patients who developed NODM after liver transplantation had a significantly reduced 5-year survival rate. John and Thuluvath 9 found that patients who developed NODM after liver transplantation experienced significantly more cardiac complications, major and minor infections, neurologic complications, and acute rejection episodes than did liver transplant recipients without NODM. There were no differences in the hospital length-of-stay or in graft and patient survival. Xu et al. 10 reported that patients with NODM had poorer overall survival and poorer tumor-free survival in patients with hepatocellular carcinoma, and a higher incidence of sepsis, fungal infections, kidney disease, and biliary complications than in patients without NODM. In contrast, Trail et al. 11 reported no difference in graft survival, number of rejection episodes, number of hospitalized days, renal function, and number of infections within 1 year following transplantation between patien...

show abstract

Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma

Cited by 24 publications

References 39 publications

Assessment and monitoring of liver function by 13C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma

Assessment and monitoring of liver function by 13C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma

An Update on 13C-Breath Tests: The Transition to Acceptability into Clinical Practice

Reversibility of posttransplantation diabetes mellitus following liver transplantation

Contact Info

Product

Resources

About